semaglutide in heart failure versus placebo patients with and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials Semaglutide in Patients with Heart
Description
Its premise is an upstream intervention targeting substantial weight reduction to improve key risk factors with the aim to avoid potential downstream complications from multiple co-morbidities, e.g., hypertension, dyslipidaemia, heart failure, kidney disease, NAFLD/NASH or diabetes
2. Metabolic Rate Boost
Support Healthy Aging and Cellular Repair
These effects are primarily seen in obese patients with preserved renal and cardiac function and may not generalize to all HFpEF phenotypes
Esta frmula um remdio para emagrecer
